ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

WSJ BLOG/Health: A.M. Vitals: Health-Care Overhaul Case Ripples Outward

(This story has been posted on The Wall Street Journal Online's Health Blog at By Mark Long Here's what's making health news this morning: Health Case Ripples Outward (WSJ): After three days of arguments over the constitutionality of the health-care overhaul, it's impossible to predict how the Supreme Court will rule, but skepticism from some justices heightens the possibility it could be overturned in June. Also: Three Days of Hearings Yield Five Take-Aways. Obesity-Linked Cancers Increase (WSJ): Overall cancer diagnoses in the U.S. have dropped, but several cancers linked to obesity and a sedentary lifestyle have risen each year from 1999 through 2008. Cancer: 'Book of Knowledge' Published (BBC): A large "encyclopedia" detailing how hundreds of different cancer cell lines interact with drugs that could speed development of new treatments was published in Nature. In Cancer Science, Many "Discoveries" Don't Hold Up (Reuters): Forty-seven of 53 "landmark" cancer studies from reputable labs couldn't be replicated, the former head of cancer research for Amgen said in a commentary piece in Nature, dimming the prospects for new drug development. FDA Asks Chelsea Therapeutics for More Data on Northera (Dow Jones Newswires): The FDA declined to approve Northera, a low-blood-pressure drug from Chelsea Therapeutics, saying additional data showing efficacy was required. Image source: iStockphoto -For continuously updated news from The Wall Street Journal, see at

Stock News for Amgen Inc. (AMGN)
11/25/201516:00:00Amgen's First Biosimilar Biologics License Application For ABP...
11/25/201509:04:03Johnson & Johnson's Latest FDA Approval Could Spell Problems...
11/24/201508:38:03Healthcare's Greatest Dividend Stocks
11/24/201502:00:00European Commission Approves Amgen's BLINCYTO® (blinatumomab...
11/23/201508:50:00CVS Chooses New Cholesterol Drug for Caremark
11/23/201508:29:00CVS Chooses Repatha as New Cholesterol Drug for Caremark
11/23/201508:10:00Amgen Announces Repatha® Preferred Position On CVS Health Commercial...
11/21/201508:00:155 Things Amgen, Inc. Wants You to Know
11/20/201518:08:02The Best Healthcare ETF of the Week
11/20/201517:44:03Better Dividend Stock: Amgen or AstraZeneca PLC?
11/19/201516:00:00European Commission Approves Kyprolis® (carfilzomib) For Combination...
11/19/201510:03:08Amgen's Repatha Is Too Bloody Pricey for the U.K.
11/17/201509:42:033 Biotech Stocks You Don't Have to Babysit
11/17/201509:42:033 Biotech Stocks You Don't Have to Babysit
11/17/201509:42:033 Biotech Stocks You Don't Have to Babysit
11/17/201509:42:033 Biotech Stocks You Don't Have to Babysit
11/16/201516:00:00Amgen to Present IMLYGIC™ (Talimogene Laherparepvec) Data at t...
11/14/201507:21:02These 2 Companies Could Revolutionize Heart Disease Prevention
11/13/201512:02:03A Bounty of Data Pushes Amgen Higher by 14% in October
11/12/201516:46:32Statement of Changes in Beneficial Ownership (4)

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations